Guide for Authors
International
Immunopharmacology
is an interdisciplinary journal devoted to the publication of original scientific papers interrelating immunology
and pharmacology. Manuscripts will be considered for publication on the condition that the results reported are based on original research
that has not been published elsewhere in any journal or language.
Types of Paper
•
Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results,
or applications. These manuscripts will undergo standard review. We emphasize that papers on
natural products must meet the following
specific criteria: a) any natural extract or drug should be fully characterized and information provided regarding origin - specifically,
the "drug" under study must have been fractionated and the active substances within the natural product identified; b) isolation or purification
techniques must be described in detail; and c) the authors must state in their paper that the material under study is endotoxin free,
including not only natural products, but also all biologics and synthetics used for immunopharmacologic studies. The Editor-in-Chief
requests that authors of Natural Product contributions read the guidelines as set out in the Editorial article of International Immunopharmacology
volume 6, issue 8.
•
Preliminary Studies/Reports. This section is for the publication of new observations that are promising
but have not achieved the stature of a regular article, yet are judged by the reviewers or editorial staff to contribute a novel, important,
or useful observation worthy of publication. These reports, including clinical studies on a limited patient population, will generally
be brief reports of a single or a few observations or results comprising up to four printed pages including all references and display
items; appropriate statistical analyses should be included.
•
Reviews are comprehensive appraisals of research and clinical
outcomes in a field of current interest. All reviews are subject to the normal review process. Please consult with the Editor-in-Chief
regarding content and length prior to submission.
• Invited
Commentary. Topical editorials, commentaries, prospective
reviews and hypotheses demonstrating acceptable standards of originality. Such articles will only be published following an invitation
to the author(s) from an Editor. Other prospective authors should obtain editorial permission before submitting a manuscript. Commentaries
(3000 words) will serve as the means for expressing controversial, critical and often personal evaluations of research trends. Commentaries
in the form of prospective reviews or hypotheses will be composite presentations of wide-ranging observations from the literature, which
should indicate, and possibly stimulate, new directions for potentially rewarding immunopharmacological research.
•
Letters
to the Editor may be considered at the discretion of the Editors.
•
Book Reviews. Books for review may be sent to
the Editor-in-Chief. Authors interested in reviewing a particular book should communicate directly with him.
•
Meeting/Symposia
reports are synopses of meetings and symposia, generally shorter than five journal pages. Please contact the Editor-in-Chief prior
to submitting. Reports must be submitted within two weeks of the end of the meeting.
•
Special Issues or Thematic Reports
are collections of full-length articles and/or reviews on a specific topic. These require approval by the Editor-in-Chief; however, recommendations
or suggestions are encouraged.
Page charges
This journal has no page charges.
Ethics in publishing
For information on Ethics in publishing
and Ethical guidelines for journal publication see
http://www.elsevier.com/publishingethics and
http://www.elsevier.com/ethicalguidelines.
Policy and ethics
Upon acceptance for publication of an article in
International Immunopharmacology
,
the author tacitly agrees to make available any materials used in the published experiments, or novel or natural products disclosed in
the article that are not commercially available, so that qualified investigators may confirm the observations.
Conflict
of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial,
personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately
influence, or be perceived to influence, their work. See also
http://www.elsevier.com/conflictsofinterest.
Submission declaration and verification
Submission of an article implies that the work described has not been
published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration
for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language,
including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the
originality detection software iThenticate. See also
http://www.elsevier.com/editors/plagdetect.
Authorship
All
authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition
of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content,
(3) final approval of the version to be submitted.
Changes to authorship
This policy concerns
the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:
Before the accepted manuscript
is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal
Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed,
or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition,
removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must
follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2)
publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.
After the accepted manuscript
is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue
will follow the same policies as noted above and result in a corrigendum.
Copyright
Upon
acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright
see
http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information.
An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement'
form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles
including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution
outside the institution and for all other derivative works, including compilations and translations (please consult
http://www.elsevier.com/permissions).
If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit
the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult
http://www.elsevier.com/permissions.
Retained author rights
As an author you (or your employer or institution) retain certain rights; for details
you are referred to:
http://www.elsevier.com/authorsrights.
Role of the funding source
You
are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly
describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing
of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this
should be stated. Please see
http://www.elsevier.com/funding.
Funding body agreements and
policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals
published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To
learn more about existing agreements and policies please visit
http://www.elsevier.com/fundingbodies.
Open access
This journal offers you the option of making your article freely available to all via the ScienceDirect
platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been
accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions
and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements
are available at
http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this
option, should complete and submit the order form (available at
http://www.elsevier.com/locate/openaccessform.pdf). Whatever
access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article
on your own website. More information can be found here:
http://www.elsevier.com/authorsrights.
Language
and language services
Please write your text in good English (American or British usage is accepted, but not a mixture
of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit
http://webshop.elsevier.com/languageservices or our customer support
site at
http://support.elsevier.com
for more information.
Submission
Submission to this journal proceeds totally online and
you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single
PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted
to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence,
including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.
For online submission to this journal please visit:
http://ees.elsevier.com/intimp.
Submit your article
Please submit your article via
http://ees.elsevier.com/intimp
Referees
Authors are encouraged to provide the names, addresses, e-mail addresses and fax numbers of up to
four researchers qualified to review the manuscript.
Use of
wordprocessing software
It is important that the file be saved in the native format of the wordprocessor used. The text
should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced
on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use
bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual
table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared
in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier:
http://www.elsevier.com/guidepublication).
Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also
the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check'
functions of your wordprocessor.
Article structure
Subdivision - numbered
sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1,
1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do
not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.
Introduction
An
Introduction should first "set the scene" for a non-specialist and then continue with
the specific reasons for undertaking the investigation. Exhaustive reviews of the literature should be avoided and no attempt should
be made to indicate the results obtained.
Materials and Methods. Procedures used should be given
in sufficient detail to permit the repetition of the work by others. However, published procedures should be briefly summarized and only
described in detail if they have been substantially modified. Special chemicals, drugs, etc. with their sources of supply should be grouped
under a separate subheading,
Materials.
Results. In this section the findings should be
described without discussion of their significance. Subsections should be used to clarify the expression of the results.
Discussion. In this section the authors' interpretations of their findings should be accompanied by an assessment
of their significance in relation to previous work. Subsections should be used wherever possible.
Essential
title page information
•
Title.
Concise and informative. Titles are often used in information-retrieval
systems. Avoid abbreviations and formulae where possible.
•
Author names and affiliations.
Where the family name
may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in
front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available,
the e-mail address of each author.
•
Corresponding author.
Clearly indicate who will handle correspondence at
all stages of refereeing and publication, also post-publication.
Ensure that telephone and fax numbers (with country and area code)
are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding
author.
•
Present/permanent address.
If an author has moved since the work described in the article was done,
or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address
at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for
such footnotes.
Abstract
Each paper must begin with an
Abstract that summarizes the
results obtained and the conclusions drawn. It should not exceed 250 words.
Graphical abstract
A
Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the
attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical
abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular
screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See
http://www.elsevier.com/graphicalabstracts
for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images
also in accordance with all technical requirements:
Illustration
Service.
Highlights
Highlights are mandatory for this journal. They consist
of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate file in the
online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including
spaces, per bullet point). See
http://www.elsevier.com/highlights for examples.
Keywords
Immediately
after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts
(avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible.
These keywords will be used for indexing purposes.
Abbreviations
The excessive use of abbreviations
in the text is strongly discouraged. In particular, awkward and unfamiliar abbreviations and those intended to express concepts or experimental
techniques will not be permitted.
Nomenclature and Units
• Drug names should be the
official or approved names; trade names or common names may be given in brackets where the drug is first mentioned. The manufacturer's
name and address must be given. The doses of the drugs should be given as unit weight/unit body weight, e.g. mmol/kg or mg/kg. Concentrations
should be given in terms of molarity (eg. nM or uM), or as unit weight/unit volume solution (eg. mg/l) stating whether the weight refers
to the salt or the active component of the drug. The molecular weight, inclusive of water of crystallization, should be stated if doses
are given as unit weight.
• Isotopic specifications should conform to the IUPAC system (Biochem. J. (1975) 145, 1-20).
• The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text.
Subsequently the
accepted trivial name shall be used, e.g.
Full Name: Acetyl-CoA:choline O-acetyltransferase (EC 2.3.1.6.)
Trivial Name: Choline acetyltransferase not choline acetylase. For this information the author should refer to
Enzyme Nomenclature
(1973), Elsevier, Amsterdam.
• Authors are requested to follow the IUPHAR Guidelines for Classification of New Receptor
Subtypes (see Immunopharmacology, Vol. 30, p. 189 or p. 255).
• Symbols for physical units should be restricted to the Systeme
Internationale (S.I.) Units. Examples of commonly used symbols can be found in Biochemical Journal 145, 1-20 (1975) and more detailed
description, in Quantities, Units and Symbols (1971) The Royal Society, London.
Database linking
Elsevier
aims at connecting online articles with external databases which are useful in their respective research communities. If your article
contains relevant unique identifiers or accession numbers (bioinformatics) linking to information on entities (genes, proteins, diseases,
etc.) or structures deposited in public databases, then please indicate those entities according to the standard explained below.
Authors
should explicitly mention the
database abbreviation (as mentioned below) together with the actual database number, bearing in
mind that an error in a letter or number can result in a dead link in the online version of the article.
Please use the following
format:
Database ID: xxxx
Links can be provided in your online article to the following databases (examples of citations are
given in parentheses):
•
ASTM: ASTM Standards Database (ASTM ID: G63)
•
CCDC: Cambridge Crystallographic Data Centre (CCDC ID: AI631510)
•
GenBank: Genetic sequence database at the National Center for
Biotechnology Information (NCBI) (GenBank ID: BA123456)
•
GEO:
Gene Expression Omnibus (GEO ID: GSE27196; GEO ID: GPL5366; GEO ID: GSM9853)
•
MI:
EMBL-EBI OLS Molecular Interaction Ontology (MI ID: 0218)
•
MINT:
Molecular INTeractions database (MINT ID: 6166710)
•
NCBI Taxonomy:
NCBI Taxonomy Browser (NCBI Taxonomy ID: 48184)
•
NCT: ClinicalTrials.gov
(NCT ID: NCT00222573)
•
OMIM: Online Mendelian Inheritance
in Man (OMIM ID: 601240)
•
PDB: Worldwide Protein Data
Bank (PDB ID: 1TUP)
•
TAIR: The Arabidopsis Information Resource
database (TAIR ID: AT1G01020)
•
UniProt: Universal Protein Resource
Knowledgebase (UniProt ID: Q9H0H5)
Footnotes
Footnotes should be used sparingly. Number
them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this
feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves
separately at the end of the article. Do not include footnotes in the Reference list.
Table footnotes
Indicate each
footnote in a table with a superscript lowercase letter.
Artwork
Electronic
artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
•
Save text in illustrations as 'graphics' or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier,
Times, Symbol.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention
for your artwork files.
• Provide captions to illustrations separately.
• Produce images near to the desired size of
the printed version.
• Submit each figure as a separate file.
A detailed guide on electronic artwork is available on our
website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the
detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is
finalised, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS: Vector drawings. Embed the font or save the text as 'graphics'.
TIFF:
Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000
dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
If your electronic artwork
is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is'.
Please do not:
•
Supply files that are optimised for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low;
• Supply files that are
too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color
artwork
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct
resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge,
that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version.
For color reproduction in print, you will receive information regarding the costs
from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or on the Web only. For
further information on the preparation of electronic artwork, please see
http://www.elsevier.com/artworkinstructions.
Please
note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should
you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the
figure. A caption should comprise a brief title (
not on the figure itself) and a description of the illustration. Keep text in
the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Number
tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them
with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables
do not duplicate results described elsewhere in the article.
References
Citation
in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any
references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference
list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference
style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'.
Citation of a reference as 'in press' implies that the item has been accepted for publication.
Web references
As
a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author
names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the
reference list) under a different heading if desired, or can be included in the reference list.
References
in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations
in the text) to other articles in the same Special Issue.
Reference management software
This
journal has standard templates available in key reference management packages EndNote (
http://www.endnote.com/support/enstyles.asp)
and Reference Manager (
http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only
need to select the appropriate journal template when preparing their article and the list of references and citations to these will be
formatted according to the journal style which is described below.
Reference style
Text:
Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s)
must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art
of writing a scientific article. J Sci Commun 2010;163:51–9.
Reference to a book:
[2] Strunk Jr W, White EB. The elements
of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
[3] Mettam GR, Adams LB. How to prepare
an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc;
2009, p. 281–304.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6
should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical
Journals' (J Am Med Assoc 1997;277:927–34) (see also
http://www.nlm.nih.gov/bsd/uniform_requirements.html).
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these
within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content
and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to
the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one
of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in
the electronic version of your article in Elsevier Web products, including ScienceDirect:
http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be
used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video
instruction pages at
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in
the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that
refer to this content.
Supplementary data
Elsevier accepts electronic supplementary material
to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting
applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online
alongside the electronic version of your article in Elsevier Web products, including ScienceDirect:
http://www.sciencedirect.com.
In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors
should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file.
For more detailed instructions please visit our artwork instruction pages at
http://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending
it to the journal for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following
items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded, and contain:
•
Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
•
Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
•
All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use
of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color
reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white
in print
• If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site at
http://support.elsevier.com.
Use of the Digital
Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists
of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication.
The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they
have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from
a document in the journal
Physics Letters B):
doi:10.1016/j.physletb.2010.09.059
When you use the DOI to create URL
hyperlinks to documents on the web, the DOIs are guaranteed never to change.
Proofs
One
set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper
proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now
provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available
free from
http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online).
The exact system requirements are given at the Adobe site:
http://www.adobe.com/products/reader/tech-specs.html.
If
you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them
to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections
and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail,
or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures.
Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor.
We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within
48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying,
as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed
with the publication of your article if no response is received.
Offprints
The corresponding
author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via
the offprint order form which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published
article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
For inquiries relating to the submission of articles (including electronic submission) please
visit this journal's homepage. Contact details for questions arising after acceptance of an article, especially those relating to proofs,
will be provided by the publisher. You can track accepted articles at
http://www.elsevier.com/trackarticle. You can also
check our Author FAQs (
http://www.elsevier.com/authorFAQ) and/or contact Customer Support via
http://support.elsevier.com.
